Article ; Online: Cyclophilin D knockout significantly prevents HCC development in a streptozotocin-induced mouse model of diabetes-linked NASH.
2024 Volume 19, Issue 4, Page(s) e0301711
Abstract: ... several cyclophilin isoforms, among which cyclophilin D (CypD) has not been previously investigated in this context ...
| Abstract | A family of Peptidyl-prolyl isomerases (PPIases), called Cyclophilins, localize to numerous intracellular and extracellular locations where they contribute to a variety of essential functions. We previously reported that non-immunosuppressive pan-cyclophilin inhibitor drugs like reconfilstat (CRV431) or NV556 decreased multiple aspects of non-alcoholic fatty liver disease (NAFLD) in mice under two different non-alcoholic steatohepatitis (NASH) mouse models. Both CRV431 and NV556 inhibit several cyclophilin isoforms, among which cyclophilin D (CypD) has not been previously investigated in this context. It is unknown whether it is necessary to simultaneously inhibit multiple cyclophilin family members to achieve therapeutic benefits or if loss-of-function of one is sufficient. Furthermore, narrowing down the isoform most responsible for a particular aspect of NAFLD/NASH, such as hepatocellular carcinoma (HCC), would allow for more precise future therapies. Features of human diabetes-linked NAFLD/NASH can be reliably replicated in mice by administering a single high dose of streptozotocin to disrupt pancreatic beta cells, in conjunction with a high sugar, high fat, high cholesterol western diet over the course of 30 weeks. Here we show that while both wild-type (WT) and Ppif-/- CypD KO mice develop multipe severe NASH disease features under this model, the formation of HCC nodules was significantly blunted only in the CypD KO mice. Furthermore, of differentially expressed transcripts in a qPCR panel of select HCC-related genes, nearly all were downregulated in the CypD KO background. Cyclophilin inhibition is a promising and novel avenue of treatment for diet-induced NAFLD/NASH. This study highlights the impact of CypD loss-of-function on the development of HCC, one of the most severe disease outcomes. |
|---|---|
| MeSH term(s) | Animals ; Humans ; Mice ; Carcinoma, Hepatocellular/genetics ; Carcinoma, Hepatocellular/prevention & control ; Carcinoma, Hepatocellular/pathology ; Cyclophilins/genetics ; Diabetes Mellitus/pathology ; Diet, High-Fat ; Disease Models, Animal ; Liver/pathology ; Liver Neoplasms/genetics ; Liver Neoplasms/prevention & control ; Liver Neoplasms/drug therapy ; Mice, Inbred C57BL ; Non-alcoholic Fatty Liver Disease/pathology ; Peptidyl-Prolyl Isomerase F ; Streptozocin |
| Chemical Substances | Cyclophilins (EC 5.2.1.-) ; Peptidyl-Prolyl Isomerase F ; Streptozocin (5W494URQ81) ; PPIF protein, mouse |
| Language | English |
| Publishing date | 2024-04-04 |
| Publishing country | United States |
| Document type | Journal Article |
| ZDB-ID | 2267670-3 |
| ISSN | 1932-6203 ; 1932-6203 |
| ISSN (online) | 1932-6203 |
| ISSN | 1932-6203 |
| DOI | 10.1371/journal.pone.0301711 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.